Hemodiafiltration reduces all-cause mortality in people with kidney failure: Lancet
A new study published in The Lancet journal showed that hemodiafiltration lowers mortality associated with kidney failure compared to hemodialysis, with dose-dependent advantages. Within 5 years of the first dialysis demand, kidney failure is linked to a death risk of almost 50%. Estimates of survival may increase with convection-based hemodialysis therapies, which eliminate a wider range of uremic chemicals than diffusive therapy.
According to randomized clinical research, individuals with kidney failure who get high-dose hemodiafiltration instead of traditional high-flux hemodialysis have a 23% decreased chance of dying. However, it is yet unknown if treatment effects vary among subgroups, if there is a dose-response connection with convection volume, and how it affects cause-specific mortality.
Thus, Robin Vernooij and colleagues presented an overview of the available data from randomized controlled studies comparing hemodiafiltration and hemodialysis that were intended to evaluate all-cause mortality in patients with renal failure is the goal of this individual patient data meta-analysis. This study wanted to offer more exact estimates of the impact of hemodiafiltration vs hemodialysis across multiple subgroups, to measure cause-specific mortality, and to provide light on the ongoing link between attained convection volume and mortality risks.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.